In the interview, the CEO and Chairman of Mutter Ventures gives all the details about what this will mean for the company, especially focused on getting more liquidity and shortening the time to achieve a return and be able to reinvest in other projects. “Our ultimate goal is for investments to have a positive and financial impact and for the projects we promote to end up with return,” Christian explains.

We are really happy and proud of the sale of our invested company CS2 to Telefónica.

Telefónica Group’s Telefónica Soluciones de Criptografía, S.A. has acquired Cryptography &
Security Systems, S.L. (known as CS2) from its 34 shareholders.
CS2 is a 100% proprietary technology with 20 years of experience, offering a
comprehensive service in the implementation, customization, and maintenance of our
secure communications systems in strategic and tactical communications.
CS2 has a multidisciplinary team made up of highly qualified telecommunications, physics
and computer engineers, who create and implement secure systems whose development is
carried out on the most advanced and reliable technologies, and who have been
recongnized by the Spanish Ministry of the Interior for the tactical communications
developed and used in the fight against terrorism

• MAFTEST^®analyses of the NSABP-B34 and AZURE landmark clinical trials confirmed clinical utility of the MAFTEST® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment.
• Reduces the risk of death at 5 and 10 years by 26% and 23% respectively.
• Identifies almost twice as many patients able to benefit from the intervention than are selected using current clinical guidelines.
• Data published in Annals of Oncology,(33), SUPPLEMENT 3, S152, 2022.

Barcelona, July 14 2022; Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients, announces the results of comparing the clinical efficacy of implementing the proprietary MAFTEST® for selection of patients for adjuvant bisphosphonates therapy with current clinical guidance. The results were presented at the ESMO 2022 Breast Cancer Symposium.

The data show that stratification of early breast cancer patients according to MAF status reduced the risk of death and relapse in MAF negative patients by 26% and 23% respectively, compared to a 12% and 15% reduction in the risk of death or relapse seen with stratification by menopausal status recommended by current ESMO and ASCO Clinical Guidelines. The data also indicate that adjuvant treatment with bisphosphonates should be avoided in MAF positive patients as the risk of death and relapse is increased 16% and 15% respectively in these patients.

In addition, the study shows that the use of MAF status for selection of early breast cancer patients for treatment with bisphosphonates allows the treatment of young premenopausal patients currently excluded by existing clinical guidance.

“The MAF biomarker allows a new paradigm for selection of patients for adjuvant bisphosphonate treatment of early breast cancer that not only identifies those patients that will benefit from treatment (MAF negatives) but also excludes patients that could be harmed (MAF positives).   This new selection criteria not only reduces the risk of death and relapse for selected patients but also provides a new treatment option for young patients currently excluded from this treatment in current clinical practice.”, said Robert Coleman, Professor Emeritus, Department of Oncology and Metabolism, University of Sheffield, UK.

Currently, clodronate and other bisphosphonates are not approved by the regulatory agencies for use in adjuvant treatment of the broad population of early-stage breast cancer patients. However, they are recommended in the ASCO/CCO and ESMO clinical guidelines for adjuvant treatment of breast cancer in postmenopausal patients. The study shows that identifying MAF-negative patients for selection for adjuvant treatment with bisphosphonates outperforms current selection by menopausal status and could give more patients, particularly younger patients, the opportunity to benefit from adjuvant bisphosphonates, while avoiding potential harm (or no benefit), than solely using menopausal status as a selection criterion.

“Our results indicate that adjuvant clodronate treatment has a large clinical benefit if restricted to MAF-negative patients.”, said Prof. Alexander Paterson, principal investigator of the NSABP-B34 clinical trial and Emeritus Clinical Professor at the Department of Oncology, University of Calgary. “Our data provide an objective criterion for patient selection for bisphosphonate adjuvant treatment that outperforms current selection based on menopausal status”.

“This study confirms our previous findings and the clinical utility of MAFTEST® as a unique tool for precision medicine in early breast cancer. Every year approximately 355,000 women are diagnosed with early breast cancer in Europe with a 10% risk of death at 5 years. Using MAF Test these deaths could be reduced by 26%, which would translate to 9,230 lives saved.”, said Joël Jean-Mairet, Executive Chairman of the Board of Inbiomotion.

“We have discovered and developed a new biomarker, MAF gene amplification, that if used as selection criteria for adjuvant treatment with bisphosphonates improves the clinical outcome of breast cancer patients compared with current clinical practice”, said Prof. Roger Gomis, ICREA Research Professor at IRB Barcelona. “MAF Test is a biomarker that is easy to implement in any clinical pathology lab and should be considered for routine characterization of breast cancer tumors”.

Recently the MAFTEST^® obtained the CE-mark as an in vitro diagnostic medical device for prognostic purposes. Since clodronate and other bisphosphonates are not approved by the regulatory agencies for use in adjuvant treatment of early-stage breast cancer patients, Inbiomotion’s MAFTEST^® is not authorized to be used as a companion diagnostic as described in the above-mentioned study.

Reference articles:

Impact of MAF selection of patients for adjuvant bisphosphonate therapy and comparison with current clinical guidance Robert Coleman, Roger R Gomis, Alexander H G Paterson.

Full text article: https://www.annalsofoncology.org/article/S0923-7534(22)00461-6/fulltext

MAF amplification and adjuvant clodronate outcomes in early-stage breast cancer in NSABP B-34 and potential impact on clinical practice Alexander H G Paterson et al.

Full text article: https://pubmed.ncbi.nlm.nih.gov/34377934/

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of international, open-label, randomized, controlled, phase 3 AZURE (BIG 01/04) trial Robert Coleman et al.

Full text article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30603-4/fulltext

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) Robert Coleman et al.

Full text article: https://pubmed.ncbi.nlm.nih.gov/30591866/

ENDS

For further information, please contact:

Joël Jean-Mairet, PhD

jjean-mairet@inbiomotion.com

www.inbiomotion.com

Optimum Strategic Communications

Mary Clark, Manel Mateus, Zoe Bolt

Tel: +44 (0) 203 922 0891

Email: inbiomotion@optimumcomms.com

Notes to Editors:

About Inbiomotion:

Inbiomotion SL, a company founded by Prof. Roger Gomis, is developing a unique single gene-based biomarker for the personalized adjuvant treatment of early-stage breast cancer patients. The biomarker has been technically and analytically validated. The results of the first trial using well annotated archived specimens of the AZURE registrational clinical trial, now confirmed in the NSABP-B34 trial, indicate its potential use as a companion diagnostic. The company holds over 200 patents and patent applications covering its proprietary FISH MAFTEST® and the use of bisphosphonates in the adjuvant treatment of early-stage breast cancer patients.

About MAF:

MAF (mesenchymal aponeurotic fibrosarcoma gene, an AP-1 family transcription factor) is expressed in primary cancer tumors. This is associated with increased metastasis, especially bone metastasis. MAF transcriptionally controls genes such PTHrP, which regulate metastasis-related cellular processes, including survival, initiation, metabolic rewiring, and particularly, adhesion to bone marrow–derived cells and osteoclast differentiation. These observations point to MAF having a key hierarchical role in metastasis.

The MGA group, led by Marisa Guitart, was key in 2013 in driving the series B financing of Sanifit, which would end up being bought by Vifor at the end of 2021.

MARISA GUITART AMECHAZURRA

TEAM PIMIENTA: ANNA, JORDI, ALBERT.

SITGES (BARCELONA), DECEMBER 2021

Eight years separate the first meeting between the heads of Sanifit and the MGA group and the millionaire sale of this Balearic biotech born in a university laboratory (UIB) to the Swiss pharmaceutical company Vifor.

We want to meet one of the protagonists, who subtly appears behind a group of people who call themselves the MGA Group.

Her name hardly appears in any of the journalistic chronicles we read about the sale of Sanifit, the largest in the history of a Spanish biotech company. Without further ado, I contact Marisa, whom I have the pleasure and pride of knowing personally, and I ask her directly about our interest in finding out what it was like, what exactly the MGA Group is, and what about Sanifit.

Our objective is for Marisa to explain to us in first person the untold story of Sanifit and its molecule SNF-472 -provisional name- because it is undoubtedly great news: if it becomes a drug, it will improve the lives of many patients with calciphylaxis and also of the peripheral arterial disease suffered by many dialysis patients.

She agrees without a moment’s hesitation. I can affirm that Marisa is like that, open, energetic, intelligent and extremely generous, I speak with knowledge of cause because I have the honor of being an ambassador of her NGO, Las Historias de Sofía. But that’s another topic, let’s get back to the million-dollar sale of Sanifit.

I travel with the team to interview Marisa Guitart Amechazurra, the initials of the veteran CEO of the business consultancy MGA Business Consulting, specialized in ‘life sciences’.

She very kindly opens the doors for us, in the best possible way. We arrive at the agreed time and Marisa leads us to her office, located in her family residence. We enter a pleasant room with large windows decorated with great taste and in which, in addition to a work table, we see a wall piano, a divan, various original objects, pieces of art and a collection of cameras and lenses … After a brief introduction of the team that accompanies me, in this case Albert, journalist, and photographer Jordi, we ask permission to start recording. We sit down and begin to discover the story behind the screen.

What is the MGA group?

The MGA group involved in this milestone story is a small group of investors who bet, when Sanifit was in active search for resources in 2013, to follow in my footsteps and venture into the project. I gathered my “fellow travelers”, people around me who believe and invest with me.

With her ego dampened by the passage of time, Marisa is eager to mention, by name and surname, all the architects of the largest biotech sale operation in Spain, not because of the economic volume, which could exceed 1 billion if everything goes well, but because if everything goes well, “many lives will be saved”.

Let’s go back to the beginning of this romance.

One day in August 2013, Guitart met Joan Perelló (CEO) and Carolina Salcedo (CSO) for the first time at a Caixa Capital Risk office in Barcelona, where Jose Antonio Mesa, the then Investment Director, was also present. All entrepreneurs, in order to grow and evolve their project, need to do rounds of financing, and Sanifit was no exception. It had managed to do a series A with Caixa Capital Risk and other business angels, but now it needed to do a larger B. It was at this point that he arrived at Marisa’s table.

We were meeting at Caixa Capital Risk and they explained to me the project of a molecule in preclinical phase, with very good results at that time. They were people who believed in what they were doing, and the results they were obtaining, even at a very early stage, completely fascinated me. I fell in love with both the project and the people. If this molecule reached the market it could save lives, and I think this is spectacular for a person who has worked all her life in life sciences like me. What more could we ask from a project?

Marisa embarked on a journey with an uncertain ending, but she didn’t do it alone. For the crew, she needed reliable people capable of weathering the storm with a cool head. “In cases like this you can’t invest the money you need to live, it’s putting money at risk, it’s like playing roulette. This was betting everything on the red 13: if the ball goes to the red 13, perfect, but if not, you have lost everything.”

He called his FFFs (Family, Fools & Friends), the partners he chose to be part of the MGA group. The first ones? Chemist Santiago Pulido and financier Jaime Nieto. They agreed that Sanifit had possibilities, they trusted in it, and that’s when it all started, we made a participative loan and we enrolled more people and I told them that if they didn’t need the money, they could help this project to move forward. It’s as “simple” as that, if you believe, work and don’t lose confidence and motivation.

At this point in the story it is important to stop for a moment to ask how Sanifit came to knock on Marisa Guitart’s door.

Who is Marisa Guitart Amechazurra?

She started working at Squibb Pharmaceuticals in 1977, at the age of 17. In 1985 she changed company, but not sector. She joined the multinational Pharmacia, where she worked for 10 years, when in 1995 she was offered the position of vice-president of Europe for the company… and she said no. Guitart argues that this position meant she would have to stay in Freiburg (Germany) and she did not feel like it.

A 35-year-old woman had never been offered such a position, but I did not accept. My family was here, I am very family-oriented, although I had no children or steady partner at the time, but my parents, my siblings and my friends were there. And I told them no, that the company car and the cell phone -that vibrated! …things of 1995- were fine, but my next purpose was to go into consulting.

On August 31, 1995, she stopped working for Pharmacia and on September 1 of the same year she was hired as an external consultant. She stayed that way for 12 years until, in 2007, her friend Santiago Pulido convinced her again to rejoin Pharmacia -then Phadia-, with the position she had rejected in 1995: vice-president of Europe. This time she accepted.

For four years we worked to improve the company, and then we sold it to a very large multinational. Then I had to decide whether to stay in that new multinational, I could do it, but I decided to leave. And I went back to consulting for good, and to my madness of helping Spanish companies. I have been here since 2011.

In that start-up in 2013 and the creation of his MGA group to get the necessary funding for the continuity of the project, Guitart tells us that there is also another key name: Jose Antonio Mesa, the Investment Director of Caixa Capital Risk at that time. In order to make the Series B, Mesa moved and found investors such as Health Equity and Somtobir. After two years, phase C was required. It is in that series C when Sanifit gives a blow on the table so that the great venture capitals of the country joined and believed in the project. Guitart is excited to recall that capital injection, the largest for a biotech in Spain at that time: 40 million dollars, about 36 million euros.

This third series was co-led by Ysios Capital, one of the most powerful venture capital firms in Spain, headed by Joel Mairet. Ysios was joined by other European venture capital firms such as Forbion, Gilde and Edmond de Rothschild Investment Partners, which is now called Andera Partners. And after that record series C, Sanifit continued to advance, now with much more strength in the sails until a series D, in which more crew members joined, such as Alta Partners and Columbus Venture Partners. And public money also came in from the CDTI (Center for Industrial Technological Development) through the Innvierte program.

At this point, after years of research and investment, we needed even more money to turn the molecule discovered by Joan Perelló and Bernat Isern in a research project at the University of the Balearic Islands into a drug.

We could have made another series, but we had foreseen other ways, such as a takeover bid in Europe or the USA, going public, or a merger or acquisition with another company.

for acquires Sanifit for an upfront payment of 204 million, then there are 170 million in pre-commercial milestones and then a series of commercial milestones that, if they are met, Sanifit investors will be paid on that basis. The time horizon is unknown, the ‘upfront payment’ you know when you will receive it, when the ‘closing’ takes place once we have the approval of the Spanish government and the US antitrust authorities. From here on, we have to continue working to integrate the teams of the two companies.

The road we have traveled in these eight years has not been covered with rose petals, far from it. There have been powerful storms that only a strong and united team has been able to weather safely and safely. Marisa Guitart wants to name that team that, “when one fell down, another one would stand up for him”. There are many people involved both in Europe and in the United States, where a team develops the clinical part, she says.

We have some very good people there, and some people who are no longer there who have played a very important role in getting this company to where it is today: Alex Gold, Claire Padget, Toni Foster; Rekha Garg, Cris Calsada, among others And we continue with excellent people in Spain Toni Jiménez, Marco Moreno and Bernat Isern ; Miguel Ortiz; Carol Salcedo , Firas Bassisi, Marc, Miki, Cristina… And then the finance team with Julià Mesquida, who is a beast… (laughs), Núria Vila our tireless executive assistant . And I would go on, as there have been many other people who have contributed to this success.

When she talks about people, her eyes shine, she increases the passion of the story, she makes it clear that the value of the team is very important for Guitart. When there are operations such as the sale to Vifor, the media spotlight tends to focus on a few people, logically from another party, but behind them there is an army rowing in the same direction.

This is not done by one person alone; it is not done by the CEO alone, nor by venture capitalists alone; this is done with a spectacular team made up of each and every one of the people who make up the team, the external consultants, and the Board of Directors.

The largest sale of a biotech start-up in Spain is a success story – of which there are very few.

Unfortunately, according to Marisa Guitart, “in the biotech field, only one in thousands of projects is successful”. And she reminds us that this is partly due to a lack of financial support. For this reason, Guitart encourages more people like her and her group MGA to make available that amount of money available to push interesting projects like Sanifit, she asks “that they do not stay in a drawer and take the step, of course, in an advised way”.

We ended our interview by talking about culture, the trend. In this country, savings and investments tend to end up in the real estate market or in various financial products; there is hardly any collaboration in R&D or science. Crowdfunding has little success except in exceptional cases. Guitart calls on public institutions, on the one hand, to make existing aid more accessible and visible and, on the other, to increase the budget.

What we have to do is to make the State aware that we have to invest in research and development, and that we have to invest in small projects of Spanish companies that have brutal projects. And I’m not just talking about money, but also about helping professionals like me, for example, who have 40 years of experience and can contribute ideas, support and backing, to get involved in projects like these. For example, there are people with fantastic projects that need someone who knows about strategy, organization or business development…..

We say goodbye. We know that Marisa Guitart is not going to sit at home on the sofa and look at the trophy for the sale of Sanifit with pride. She assures us that she will continue to support Sanifit, and that there will be more. Because there are many projects, some spectacular as she says, and disruptive, brilliant projects that need support, both financial and operational. This milestone in the history of Spanish biotechnology is a good example.

You have to move and take risks. I have supported other companies and I have fallen, with impressive setbacks, but I am still confident in what I do and the MGA group is still alive helping other companies. I still believe in what I believe in, firmly.

• Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio
• Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor of vascular calcification in phase 3, developed for the treatment of calcific uremic arteriolopathy (CUA) and peripheral artery disease (PAD) in patients with end-stage kidney disease
• Purchase price includes an upfront payment of EUR 205 million, precommercial milestones for up to EUR 170 million and progressive commercial milestones

St. Gallen, Switzerland, and Palma, Spain, 19 November 2021 – Vifor Pharma and Sanifit Therapeutics, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the companies have entered into a definitive agreement. Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease. There are currently no approved medicines indicated for CUA or for PAD specifically in this population. SNF472 has already been granted orphan drug designation for the treatment of CUA and PAD by the US Food and Drug Administration and for CUA by the European Medicines Agency.
Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company’s portfolio of innovative assets. Shareholders of Sanifit will receive an upfront payment of EUR 205 million, clinical, regulatory and market access milestones for up to EUR 170 million and tiered sales-based milestones that could reach mid to high triple digit EUR millions at peak sales.
“Today’s exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally”, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group. “Through the acquisition of Sanifit and its lead compound SNF472, we will further expand our growing nephrology pipeline into vascular calcification, a major cause of morbidity and mortality in patients with end-stage kidney disease. SNF472 is the only novel asset addressing a great unmet medical need for end-stage kidney disease patients with calcific uremic arteriolopathy and peripheral artery disease. We look forward to bringing this highly promising, innovative treatment option to over 330,000 patients in the US and Europe, living with CUA or PAD, as soon as possible.”
Joan Perelló, Ph.D., Chief Executive Officer of Sanifit, said; “From the very beginning, Sanifit has been a pioneer of new approaches to treat calcification disorders, a huge area of unmet need. This agreement is a testament to the enduring commitment of our dedicated team and investors, as well as our unique approach to combat vascular calcification, which originated from the University of the Balearic Islands. We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies. Vifor Pharma is the ideal partner to take the development of Sanifit’s calcification franchise forward and bring these novel treatments to patients as quickly as possible.”
Sanifit conducted a phase-IIb trial (CaLIPSO) to assess the effect of SNF472 on slowing arterial calcification, a major risk factor for cardiovascular disease in dialysis patients. The trial met its primary endpoint in reducing coronary artery calcium progression in patients treated with SNF472, compared to patients receiving placebo over a 52-week period. SNF472 is currently in phase-III trials in CUA in patients on dialysis, to measure primary endpoints for wound healing and pain. A phase-III trial in PAD in patients on dialysis, is planned to commence in 2022.
Closing of the transaction is contingent on customary closing conditions, including the FDI procedure in Spain and merger filings in certain countries, and is expected to take place in Q1 2022.
Contact and further information:
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

Sanifit:
Joan Perelló, CEO
Investor.Relations@sanifit.com

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.

About Sanifit Therapeutics
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders. The Company is a spin-off from the University of the Balearic Islands and has offices in Spain and the U.S. Sanifit’s lead asset, SNF472, successfully completed a Phase 2 proof of concept study in calciphylaxis, and showed a significant reduction in progression of coronary calcification in a Phase 2b study in hemodialysis patients. A Phase 3 pivotal study in calciphylaxis is currently underway and the Company is also pursuing peripheral arterial disease (PAD) in patients with end-stage kidney disease as a second indication for SNF472. In 2015 and 2019, Sanifit announced the largest private biotech fundraises in Spain and has been supported by a variety of healthcare focused investors including: Caixa Capital Risc, Ysios Capital, Lundbeckfonden Ventures, Forbion Capital Partners, Gilde Healthcare, Andera Partners, Columbus Venture Partners, Alta Life Sciences, Baxter Ventures, HealthEquity and INNVIERTE ECONOMÍA SOSTENIBLE, a venture capital fund managed by the Centre for the Development of Industrial Technology (“CDTI”) of the Spanish Government. Sanifit is headquartered in Palma, Spain.
About SNF472
SNF472 is an intravenously administered selective calcification inhibitor, developed by Sanifit as a potential treatment for peripheral artery disease (PAD) and calcific uremic arteriolopathy (CUA) in hemodialysis, both rare diseases related to progressive cardiovascular calcification (CVC).
About CUA
Calcific uremic arteriolopathy also known as Calciphylaxis (CUA), is a rare but potentially devastating condition most often observed in patients with end-stage renal disease (ESRD), although it does occasionally develop in patients without renal failure. Calciphylaxis is a severe form of CVC in which the calcium deposits block small blood vessels in skin and fat tissue. These blockages cause the development of intensely painful and debilitating chronic skin lesions. Calciphylaxis is a devastating rare disease that affects 1-4% of dialysis patients and has a 1-year mortality rate of 55%.
About PAD
Peripheral artery disease (PAD) in end-stage kidney disease (ESKD) affects patients who depend on ongoing renal replacement therapy, most commonly hemodialysis. PAD causes patients to reduce their mobility, have pain in lower extremities, and can lead to chronic limb threatening ischemia and amputation. PAD is a marker for vascular calcification – a major contributing cause of death among patients in dialysis.

The financing round is led by Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC. Existing investors including Institut Català de Finances (ICF) have also participated in the financing.

Inbiomotion is in advanced stage of development of a single gene-based test for predicting response to bisphosphonates in breast cancer adjuvant setting and prevent metastasis.

The capital increase is intended to complete regulatory development to commercialize next year.

Inbiomotion’s product addresses a significant companion diagnostics market globally.

Barcelona January 21st, 2021.- Inbiomotion SL today announced that Alta Life Sciences has led its significantly oversubscribed investment round. Alta Life Sciences Spain I FCR is a leading venture capital fund managed by Altamar Private Equity SGIIC.

Inbiomotion is focused on providing a unique companion diagnostic solution addressing an urgent and unmet medical need in the personalized adjuvant treatment of early-stage breast cancer patients. Founded in 2010 by Prof. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions.

Inbiomotion’s unique diagnostic assay is based on a highly selective single gene predictive biomarker. Data generated thus far demonstrates that such biomarker (MAF test) can identify early-stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment, improving their overall and disease-free survival. It can further predict at an early stage a patient’s risk of metastasic relapse from primary tumors.

Joël Jean-Mairet, Chairman of Inbiomotion and Managing Partner at Ysios Capital, said “We are very excited with this highly oversubscribed financing round, which will unfold the full potential of our work and impact over 700,000 early-stage breast cancer patients diagnosed every year. Improving their treatment options through a unique personalized medicine is our driving force”.

Professor Roger R. Gomis, founder of Inbiomotion and a renowned researcher in metastasis, said: “We are delighted to have the support of Alta LS. This funding is a qualitative and quantitative leap forward that will allow us to complete regulatory and commercial development validation and placing MAF test within the reach of patients”.

José Antonio Mesa, Partner at Alta Life Sciences, and joining the Board of Inbiomotion said: “Alta looks to invest in potential world class opportunities by backing great teams and ground-breaking science in areas of major unmet medical need. Metastasis prevention remains an enormous challenge and the cause of over 90% of all cancer deaths worldwide. Inbiomotion is in a unique position, poised to commercialize a new personalized treatment option to save patients’ lives next year”.

About Inbiomotion:

Inbiomotion SL, a company founded by Prof Dr Roger Gomis, is developing a unique single gene-based biomarker for the personalized adjuvant treatment of early-stage breast cancer patients. The biomarker has been technically and analytically validated. The results of two major studies, using archived specimens of the AZURE and NSABP B34 registrational clinical trials, indicate its potential use as a companion diagnostic with a clear clinical utility. Inbiomotion holds over 180 patents and patent applications covering its proprietary MAF test and the use of bisphosphonates in the adjuvant treatment of early-stage breast cancer patients.

www.inbiomotion.com